NEW YORK, Sept. 22, 2016 /PRNewswire/ -- Attorney
Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies
investors that a class action lawsuit has been filed against
Spectrum Pharmaceuticals Inc. ("Spectrum" or the "Company")
(NASDAQ: SPPI) and certain of its officers. The class action
is on behalf of a class consisting of all persons or entities who
purchased Spectrum securities between December 16, 2015 through September 16, 2016, inclusive (the "Class
Period").
This class action seeks to recover damages against Defendants
for alleged violations of the federal securities laws under the
Securities Exchange Act of 1934 (the "Exchange Act").
The Complaint alleges that throughout the Class Period
defendants made false and/or misleading statements and/or failed to
disclose that: (1) the Food and Drug Administration (the "FDA")
previously questioned whether the data from the 611 and 612 Studies
were clinically significant; (2) the FDA instructed defendants in
December 2012 not to submit the New
Drug Application based on data from the 611 and 612 Studies; and
(3) consequently, defendants' public statements regarding the
Company's business, operations and prospects were materially false
and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to
review a copy of the Complaint you can visit the firm's site:
http://www.bgandg.com/sppi or you may contact Peretz Bronstein, Esq. or his Investor Relations
Analyst, Yael Hurwitz of Bronstein,
Gewirtz & Grossman, LLC at 212-697-6484 or via email
info@bgandg.com. Those who inquire by e-mail are encouraged to
include their mailing address and telephone number. If you
suffered a loss in Spectrum you have until November 21, 2016 to request that the Court
appoint you as lead plaintiff. Your ability to share in any
recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael
Hurwitz
212-697-6484 | info@bgandg.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-notifies-investors-of-class-action-against-spectrum-pharmaceuticals-inc-sppi-and-lead-plaintiff-deadline-november-21-2016-300332720.html
SOURCE Bronstein, Gewirtz & Grossman, LLC